Targeted therapies and clinical trials in ovarian cancer

Annals of Oncology

Volumn 24, Issue SUPPL.10, 2013, Pages

  Dancey, J ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Genomics; Ovarian cancer; Targeted drugs; Trial designs

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; AFATINIB; AFURESERTIB; ANAPLASTIC LYMPHOMA KINASE; ARRY 438162; B RAF KINASE; BUPARLISIB; BYL 719; COBIMETINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; INIPARIB; IPATASERTIB; LAPATINIB; MK 0752; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PD 03329912; PERTUZUMAB; PICTILISIB; RUCAPARIB; SELUMETINIB; TAXANE DERIVATIVE; TEMSIROLIMUS; TRAMETINIB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELIPARIB; VEMURAFENIB;

ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CLEAR CELL CARCINOMA; CLINICAL TRIAL (TOPIC); COPY NUMBER VARIATION; DRUG SENSITIVITY; GENE AMPLIFICATION; HIGH GRADE SEROUS OVARIAN CARCINOMA; HOMOLOGOUS RECOMBINATION; HUMAN; OVARIAN CLEAR CELL CARCINOMA; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; SOMATIC MUTATION;

GENOMICS; OVARIAN CANCER; TARGETED DRUGS; TRIAL DESIGNS;

CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 84888249547     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt473     Document Type: Article

References (37)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
2. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005; 16: 481-488.
3. Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin 2011; 61: 183-203.
4. Kurman RJ, Shih Ie M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010; 34: 433-443.
5. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-615.
6. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.
7. Flaherty KT, Robert C, Hersey P et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012; 367: 107-114.
8. Corcoran RB, Ebi H, Turke AB et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2012; 2: 227-235.
9. Finn RS, Crown JP, Lang I et al. Results of a randomized phase 2 study of pD 0332991, a cyclin-dependent kinase (cdk) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of er+/her2-advanced breast cancer (BC). Cancer Research 2012; 72(24, Suppl 3): S1-S6.
10. du Bois A, Luck HJ, Meier W et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003; 95: 1320-1329.
11. Piccart MJ, Bertelsen K, James K et al. Randomized intergroup trial of cisplatinpaclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000; 92: 699-708.
12. Tan DS, Kaye S. Ovarian clear cell adenocarcinoma: a continuing enigma. J Clin Pathol 2007; 60: 355-360.
13. Winter WE, III, Maxwell GL, Tian C et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007; 25: 3621-3627.
14. Tan DS, Iravani M, McCluggage WG et al. Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas. Clin Cancer Res 2011; 17: 1521-1534.
15. Tan DS, Lambros MB, Rayter S et al. PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. Clin Cancer Res 2009; 15: 2269-2280.
16. Natrajan R, Lambros MB, Rodriguez-Pinilla SM et al. Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin Cancer Res 2009; 15: 2711-2722.
17. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684.
18. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-1672.
19. Okines AF, Cunningham D. Trastuzumab in gastric cancer. Eur J Cancer 2010; 46: 1949-1959.
20. Bookman MA, Darcy KM, Clarke-Pearson D et al. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 2003; 21: 283-290.
21. Nielsen DL, Kumler I, Palshof JA et al. Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Breast 2013; 22: 1-12.
22. Verma S, Miles D, Gianni L et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367: 1783-1791.
23. Stany MP, Vathipadiekal V, Ozbun L et al. Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. PLoS One 2011; 6: e21121.
24. Plaxe SC. Epidemiology of low-grade serous ovarian cancer. Am J Obstet Gynecol 2008; 198: 459.e451-459.e458; discussion 459.e458-459.e459.
25. Romero I, Sun CC, Wong KK et al. Low-grade serous carcinoma: new concepts and emerging therapies. Gynecol Oncol 2013; 130(3): 660-666.
26. Farley J, Brady WE, Vathipadiekal V et al. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, singlearm, phase 2 study. Lancet Oncol 2013; 14: 134-140.
27. Gilks CB. Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data. Int J Gynecol Pathol 2004; 23: 200-205.
28. Seidman JD, Kurman RJ, Ronnett BM. Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol 2003; 27: 985-993.
29. Hess V, A'Hern R, Nasiri N et al. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol 2004; 22: 1040-1044.
30. Sato S, Itamochi H, Kigawa J et al. Combination chemotherapy of oxaliplatin and 5-fluorouracil may be an effective regimen for mucinous adenocarcinoma of the ovary: a potential treatment strategy. Cancer Sci 2009; 100: 546-551.
31. Anglesio MS, Kommoss S, Tolcher MC et al. Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. J Pathol 2013; 229: 111-120.
32. Korn EL, McShane LM, Freidlin B. Statistical challenges in the evaluation of treatments for small patient populations. Sci Transl Med 2013; 5: 178sr173.
33. McShane LM, Hunsberger S, Adjei AA. Effective incorporation of biomarkers into phase II trials. Clin Cancer Res 2009; 15: 1898-1905.
34. Belden S, Flaherty KT. MEK and RAF inhibitors for BRAF-mutated cancers. Expert Rev Mol Med 2012; 14: e17.
35. Heidorn SJ, Milagre C, Whittaker S et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010; 140: 209-221.
36. Shaw AT, Kim DW, Nakagawa K et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013; 368: 2385-2394.
37. Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363: 1693-1703.